216 related articles for article (PubMed ID: 34958778)
1. High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.
Romero LA; Hattori T; Ali MAE; Ketavarapu G; Koide A; Park CY; Koide S
J Mol Biol; 2022 Mar; 434(5):167402. PubMed ID: 34958778
[TBL] [Abstract][Full Text] [Related]
2. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
[TBL] [Abstract][Full Text] [Related]
3. CD99 antibody disrupts T-cell acute lymphoblastic leukemia adhesion to meningeal cells and attenuates chemoresistance.
Ebadi M; Jonart LM; Ostergaard J; Gordon PM
Sci Rep; 2021 Dec; 11(1):24374. PubMed ID: 34934147
[TBL] [Abstract][Full Text] [Related]
4. Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.
Cox CV; Diamanti P; Moppett JP; Blair A
PLoS One; 2016; 11(10):e0165210. PubMed ID: 27764235
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia.
Vaikari VP; Park M; Keossayan L; MacKay JA; Alachkar H
Nanomedicine; 2020 Oct; 29():102236. PubMed ID: 32535112
[TBL] [Abstract][Full Text] [Related]
6. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma.
Takheaw N; Sittithumcharee G; Kariya R; Kasinrerk W; Okada S
Cancer Immunol Immunother; 2021 Jun; 70(6):1557-1567. PubMed ID: 33215253
[TBL] [Abstract][Full Text] [Related]
7. CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia.
Kotemul K; Kasinrerk W; Takheaw N
Explor Target Antitumor Ther; 2024; 5(1):96-107. PubMed ID: 38468825
[TBL] [Abstract][Full Text] [Related]
8. CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity.
Husak Z; Dworzak MN
Cell Death Dis; 2012 Nov; 3(11):e425. PubMed ID: 23152061
[TBL] [Abstract][Full Text] [Related]
9. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.
Manara MC; Terracciano M; Mancarella C; Sciandra M; Guerzoni C; Pasello M; Grilli A; Zini N; Picci P; Colombo MP; Morrione A; Scotlandi K
Oncotarget; 2016 Nov; 7(48):79925-79942. PubMed ID: 27835596
[TBL] [Abstract][Full Text] [Related]
10. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
Tavakkoli M; Chung SS; Park CY
Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome Analysis Reveals the Induction of Apoptosis-Related Genes by a Monoclonal Antibody against a New Epitope of CD99 on T-Acute Lymphoblastic Leukemia.
Takheaw N; Kotemul K; Chaiwut R; Pata S; Laopajon W; Rangnoi K; Yamabhai M; Kasinrerk W
Antibodies (Basel); 2024 May; 13(2):. PubMed ID: 38804310
[TBL] [Abstract][Full Text] [Related]
12. Production and characterization of monoclonal antibodies against recombinant extracellular domain of CD99.
Thangaretnam KP; Paramasivam OR; Ramanathan P; Gopisetty G; Rajkumar T
Hum Antibodies; 2019; 27(1):69-83. PubMed ID: 30282350
[TBL] [Abstract][Full Text] [Related]
13. Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation.
Laopajon W; Pata S; Takheaw N; Surinkaew S; Khummuang S; Kasinrerk W
Cell Immunol; 2019 Jan; 335():51-58. PubMed ID: 30396687
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
15. Cell Adhesion Molecule CD99 in Cancer Immunotherapy.
Yu F; Liu G; Zhang H; Wang X; Wu Z; Xu Q; Wu Y; Chen D
Curr Mol Med; 2023; 23(10):1028-1036. PubMed ID: 36214301
[TBL] [Abstract][Full Text] [Related]
16. CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis.
Dorfman DM; Kraus M; Perez-Atayde AR; Barnhill RL; Pinkus GS; Granter SR
Mod Pathol; 1997 Apr; 10(4):283-8. PubMed ID: 9110288
[TBL] [Abstract][Full Text] [Related]
17. TDT (-), KIT (+), CD34 (+), CD99 (+) precursor T lymphoblastic leukemia/lymphoma.
Terada T
Int J Clin Exp Pathol; 2012; 5(2):167-70. PubMed ID: 22400079
[TBL] [Abstract][Full Text] [Related]
18. MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities.
Soslow RA; Bhargava V; Warnke RA
Hum Pathol; 1997 Oct; 28(10):1158-65. PubMed ID: 9343323
[TBL] [Abstract][Full Text] [Related]
19. CD99 is a therapeutic target on disease stem cells in myeloid malignancies.
Chung SS; Eng WS; Hu W; Khalaj M; Garrett-Bakelman FE; Tavakkoli M; Levine RL; Carroll M; Klimek VM; Melnick AM; Park CY
Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123069
[TBL] [Abstract][Full Text] [Related]
20. Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors.
Husak Z; Printz D; Schumich A; Pötschger U; Dworzak MN
J Leukoc Biol; 2010 Aug; 88(2):405-12. PubMed ID: 20453109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
